Physician profile
Daniel D Dstteffano
NPI 1740531011
$4,461.94
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $755 · 2021: $1,541 · 2022: $592 · 2023: $507 · 2024: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.54 | 2021-2023 | Vraylar |
| Glaxosmithkline, LLC. | $384.56 | 2019-2023 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $346.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $316.61 | 2019-2024 | |
| Lilly USA, LLC | $300.42 | 2019-2024 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $281.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $275.15 | 2019-2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $246.97 | 2019-2022 | |
| Amgen INC. | $227.70 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $206.85 | 2022-2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.21 | 2019-2022 | |
| Novo Nordisk INC | $196.59 | 2020-2024 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $149.75 | 2022-2024 | Austedo Xr, Ajovy |
| Nestle Healthcare Nutrition INC. | $93.51 | 2021 | |
| Pfizer INC. | $90.90 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $80.19 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.19 | 2022 | |
| Exact Sciences Corporation | $66.84 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $59.36 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $56.44 | 2019-2022 | |
| Vivus LLC | $48.96 | 2021 | |
| Sun Pharmaceutical Industries INC. | $35.46 | 2021-2022 | |
| Amarin Pharma, INC. | $25.64 | 2019-2022 | |
| Abbott Laboratories | $22.87 | 2022 | |
| Shield Therapeutics INC | $22.10 | 2023 | Accrufer |
| Acorda Therapeutics, INC | $22.01 | 2019 | |
| Daiichi Sankyo INC. | $21.06 | 2019 | |
| Neurocrine Biosciences, INC. | $17.84 | 2021 | |
| Alkermes, INC. | $15.49 | 2019 | |
| Esperion Therapeutics, INC. | $15.21 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.56 | 2021 | |
| Merck Sharp & Dohme LLC | $14.48 | 2019 | |
| Biogen, INC. | $14.31 | 2020 | |
| Radius Health, INC. | $13.91 | 2019 | |
| Galderma Laboratories, L.P. | $13.64 | 2021 | |
| Vanda Pharmaceuticals INC. | $11.74 | 2021 | |
| Ethicon US, LLC | $11.60 | 2019 | |
| Evoke Pharma, INC. | $11.45 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dstteffano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.